Hepatocellular Carcinoma

Pre-Surgical Therapy Indicated When Index Value is Low

Published in Hepatitis Weekly, February 28th, 2000

Researchers in France have evidence that hepatic transarterial chemoembolization (TACE) will benefit some hepatocellular carcinoma (HCC) patients if performed prior to hepatectomy.

Patients with an index value of 0.91 or less after undergoing a test to assess hepatic functional reserve seem to be the best candidates for this therapy, according to the researchers. The test, Technetium-99m diethylenetriamine pentaacetic acid-galactosyl human serum albumin (TC-GSA) liver scintigraphy, is used to calculate the index ratio of liver to heart-plus-liver 15 minutes after patient injection (LHL15). This index value of >0.91 is also used to determine whether surgery will be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-02-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry